UroGen Pharma Ltd. (URGN) › Cash & EquivalentsUroGen Pharma Ltd. (URGN) — Cash & EquivalentsAnnual figures by period end, from SEC filings.2014-12-31: $3.87M2015-12-31: $17.98M2016-12-31: $21.36M2017-12-31: $37.00M2018-12-31: $101.32M2019-12-31: $49.69M2020-12-31: $52.86M2021-12-31: $44.36M2022-12-31: $55.41M2023-12-31: $95.00M2024-12-31: $171.99M2025-12-31: $110.75M$110.75M2014-12-31Cash & Equivalents (USD)2025-12-31Period endedCash & EquivalentsChange YoYSource filing2025-12-31$110.75M-35.6%2026-03-02Balance as of period end2024-12-31$171.99M+81.0%2026-03-02Balance as of period end2023-12-31$95.00M+71.5%2025-03-10Balance as of period end2022-12-31$55.41M+24.9%2024-03-14Balance as of period end2021-12-31$44.36M-16.1%2023-03-24Balance as of period end2020-12-31$52.86M+6.4%2022-03-21Balance as of period end2019-12-31$49.69M-51.0%2021-03-18Balance as of period end2018-12-31$101.32M+173.8%2020-03-02Balance as of period end2017-12-31$37.00M+73.2%2019-02-28Balance as of period end2016-12-31$21.36M+18.8%2018-03-15Balance as of period end2015-12-31$17.98M+364.5%2018-03-15Balance as of period end2014-12-31$3.87M—2018-03-15Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)